Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Opportunistic Infections × Nucleosides × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 1 Opportunistic Infections 1 Inflammation 1 Hepatitis B, Chronic 1 Hepatitis B 1 Heartburn 1 Epstein-Barr Virus Infections 1 Cytomegalovirus Infections 1 Coinfection 1 Carcinoma, Hepatocellular 1 Acquired Immunodeficiency Syndrome 1

Interventions

dolutegravir 1 Ritonavir 1 Nucleosides 1 Darunavir 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04183738 2020-11-10

i2-D²EFT

Kirby Institute

Phase 4 Withdrawn

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Inflammation, Opportunistic Infections, Epstein-Barr Virus Infections, Coinfection

Data powered by HemOnc (CC BY 4.0) Colophon ⚡